Most U.S. IP teams track China through the lens of patent linkage being a single, monolithic conceptfile once, then the system plays out predictably. But the reality is less stable than most playbooks assume. Recent changes to Chinas patent linkage sys…
The China Patent Linkage System Changed in Ways Most US IP Teams Haven’t Noticed Read Post »
A drug patent can be owned on paperyet effectively controlled by someone else.
Thats the uncomfortable reality DrugPatentWatch highlights in its latest piece: when a new owner fails to file the patent assignment properly, the chain of control can fract…
The New Owner Didn’t File the Patent. Here’s Who Actually Controls It. Read Post »
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar
For investors, the biosimilar story has been one of the most reliable value creation engines in healthcareuntil you look at antibody-drug conjugates.
So far, the scorecard is zero…
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar Read Post »
CRISPR was supposed to be protected by platform patents. Fourteen years later, the litigation story says: not really.
For years, the gene-editing industry has operated on a kind of legal common sense: broad, platform patents would establish stable grou…
Stop Tracking Drug Patents. Start Tracking Who Controls Them.
Drug patent analytics used to be a clean story: list the patents, map the expirations, forecast generic entry. It was orderlyalmost spreadsheet-predictable. But the market doesnt move in str…
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
No AI Has Ever Been Named an Inventor on a Drug PatentHeres the Rule That Guarantees It
If youve followed the AI headline cycle lately, youve probably seen the recurring claim: AI will soon be an inventor on patents. It sounds inevitableuntil you look …
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
Google Patents wasnt built for pharma. Heres what it misses every time you search a drug name.
Pharma teams dont Google patentsthey interrogate them.
Yet the moment you type a molecule, a brand name, or an ingredient into Google Patents, youre likely g…
Google Patents Wasnt Built for PharmaHeres What It Misses Every Time You Search a Drug Name
Most people search Google the way they search for truth: type a name, hit enter, and assume the system will surface what matters.
But if youre in pharmaregula…
The Free Patent Database Isnt FreeIts Costing You Thousands an Hour
Theres a special kind of corporate mythology: the idea that if something is free, the work to use it is also free.
Its a comforting beliefuntil you try to use a so-called free patent d…
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
A spreadsheet of patent expiration dates isnt a strategy. Its a liabilitywith a due date.
Drug developers and strategics teams have been doing it for years: pull the database, sort the expiration calendar, flag the must-win molecules, and assign intern…
Get new actionable insights and updates from BiotechBlog
